Search

Your search keyword '"Campodonico, Jene"' showing total 4 results
Start Over Author "Campodonico, Jene"
4 results on '"Campodonico, Jene"'

1. Cell Surface Platelet Tissue Factor Expression: Regulation by P2Y12 and Link to Residual Platelet Reactivity

Author

Brambilla, Marta, Becchetti, Alessia, Rovati, Gian Enrico, Cosentino, Nicola, Conti, Maria, Canzano, Paola, Giesen, Peter L A, Loffreda, Alessia, Bonomi, Alice, Cattaneo, Marco, De Candia, Erica, Podda, Gian Marco, Trabattoni, Daniela, Werba, Pablo Josè, Campodonico, Jene, Pinna, Christian, Marenzi, Giancarlo, Tremoli, Elena, Camera, Marina, De Candia, Erica (ORCID:0000-0003-0942-2819), Brambilla, Marta, Becchetti, Alessia, Rovati, Gian Enrico, Cosentino, Nicola, Conti, Maria, Canzano, Paola, Giesen, Peter L A, Loffreda, Alessia, Bonomi, Alice, Cattaneo, Marco, De Candia, Erica, Podda, Gian Marco, Trabattoni, Daniela, Werba, Pablo Josè, Campodonico, Jene, Pinna, Christian, Marenzi, Giancarlo, Tremoli, Elena, Camera, Marina, and De Candia, Erica (ORCID:0000-0003-0942-2819)

Abstract

BACKGROUND: ADP-induced platelet activation leads to cell surface expression of several proteins, including TF (tissue factor). The role of ADP receptors in platelet TF modulation is still unknown. We aimed to assess the (1) involvement of P2Y(1) and P2Y(12) receptors in ADP-induced TF exposure; (2) modulation of TFpos-platelets in anti-P2Y(12)-treated patients with coronary artery disease. Based on the obtained results, we revisited the intracellular localization of TF in platelets.METHODS: The effects of P2Y(1) or P2Y(12) antagonists on ADP-induced TF expression and activity were analyzed in vitro by flow cytometry and thrombin generation assay in blood from healthy subjects, P2Y(12)(-/-), and patients with gray platelet syndrome. Ex vivo, P2Y(12) inhibition of TF expression by clopidogrel/prasugrel/ticagrelor, assessed by VASP (vasodilator-stimulated phosphoprotein) platelet reactivity index, was investigated in coronary artery disease (n=238). Inhibition of open canalicular system externalization and electron microscopy (TEM) were used for TF localization.RESULTS: In blood from healthy subjects, stimulated in vitro by ADP, the percentage of TFpos-platelets (17.3 +/- 5.5%) was significantly reduced in a concentration-dependent manner by P2Y(12) inhibition only (-81.7 +/- 9.5% with 100 nM AR-C69931MX). In coronary artery disease, inhibition of P2Y(12) is paralleled by reduction of ADP-induced platelet TF expression (VASP platelet reactivity index: 17.9 +/- 11%, 20.9 +/- 11.3%, 40.3 +/- 13%; TFpos-platelets: 10.5 +/- 4.8%, 9.8 +/- 5.9%, 13.6 +/- 6.3%, in prasugrel/ticagrelor/clopidogrel-treated patients, respectively). Despite this, 15% of clopidogrel good responders had a level of TFpos-platelets similar to the poor-responder group. Indeed, a stronger P2Y(12) inhibition (130-fold) is required to inhibit TF than VASP. Thus, a VASP platelet reactivity index <20% (as in prasugrel/ticagrelor-treated patients) identifies patients with TFpos-platelets <20% (92% se

Published
2023

2. The importance of re-evaluating the risk score in heart failure patients: An analysis from the Metabolic Exercise Cardiac Kidney Indexes (MECKI) score database

Author

Beatrice Pezzuto, Massimo Piepoli, Arianna Galotta, Susanna Sciomer, Denise Zaffalon, Domenico Filomena, Carlo Vignati, Mauro Contini, Marina Alimento, Nikita Baracchini, Anna Apostolo, Pietro Palermo, Massimo Mapelli, Elisabetta Salvioni, Cosimo Carriere, Marco Merlo, Silvia Papa, Jeness Campodonico, Roberto Badagliacca, Gianfranco Sinagra, Piergiuseppe Agostoni, Pezzuto, Beatrice, Piepoli, Massimo, Galotta, Arianna, Sciomer, Susanna, Zaffalon, Denise, Filomena, Domenico, Vignati, Carlo, Contini, Mauro, Alimento, Marina, Baracchini, Nikita, Apostolo, Anna, Palermo, Pietro, Mapelli, Massimo, Salvioni, Elisabetta, Carriere, Cosimo, Merlo, Marco, Papa, Silvia, Campodonico, Jene, Badagliacca, Roberto, Sinagra, Gianfranco, and Agostoni, Piergiuseppe

Subjects
Prognosi, renal function, heart failure, Heart failure, exercise capacity, hemoglobin, prognosis, risk stratification, Exercise capacity, Hemoglobin, Cardiology and Cardiovascular Medicine, Risk stratification, Renal function
Abstract

Background: The role of risk scores in heart failure (HF) management has been highlighted by international guidelines. In contrast with HF, which is intrinsically a dynamic and unstable syndrome, all its prognostic studies have been based on a single evaluation. We investigated whether time-related changes of a well-recognized risk score, the MECKI score, added prognostic value. MECKI score is based on peak VO2, VE/VCO2 slope, Na+, LVEF, MDRD and Hb. Methods: A multi-centre retrospective study was conducted involving 660 patients who performed MECKI re-evaluation at least 6 months apart. Based on the difference between II and I evaluation of MECKI values (MECKI II - MECKI I = ∆ MECKI) the study population was divided in 2 groups: those presenting a score reduction (∆ MECKI 0, clinical deterioration). Results: The prognostic value of MECKI score is confirmed also when re-assessed during follow-up. The group with improved MECKI (366 patients) showed a better prognosis compared to patients with worsened MECKI (294 patients) (p < 0.0001). At 1st evaluation, the two groups differentiated by LVEF, VE/VCO2 slope and blood Na+ concentration, while at 2nd evaluation they differentiated in all 6 parameters considered in the score. The patients who improved MECKI score, improved in all components of the score but hemoglobin, while patients who worsened the score, worsened all parameters. Conclusions: This study shows that re-assessment of MECKI score identifies HF subjects at higher risk and that score improvement or deterioration regards several MECKI score generating parameters confirming the holistic background of HF.

Published
2023

3. Dose-dependent efficacy of β-blocker in patients with chronic heart failure and atrial fibrillation

Author

Michele Correale, Domenico Scrutinio, Stefania Paolillo, Gaia Cattadori, Marco Metra, Gianfranco Sinagra, Jeness Campodonico, Giuseppe Pacileo, Simone Binno, Massimo Mapelli, Angela Beatrice Scardovi, Marco Guazzi, Carlo Vignati, Susanna Sciomer, Massimo F Piepoli, Michele Emdin, Claudio Passino, Elisa Battaia, Pasquale Perrone Filardi, Andrea Di Lenarda, Piergiuseppe Agostoni, Carlo Lombardi, Fabrizio Veglia, Aldo P. Maggioni, Damiano Magrì, Giuseppe Limongelli, Chiara Minà, Federica Re, Elisabetta Salvioni, Maurizio Bussotti, Ugo Corrà, Francesco Clemenza, Michele Senni, Roberto Badagliacca, Rosa Raimondo, Rocco Lagioia, Alice Bonomi, Mariantonietta Cicoira, Maria Frigerio, Enrico Perna, Gianfranco Parati, Campodonico, Jene, Piepoli, Massimo, Clemenza, Francesco, Bonomi, Alice, Paolillo, Stefania, Salvioni, Elisabetta, Corrà, Ugo, Binno, Simone, Veglia, Fabrizio, Lagioia, Rocco, Sinagra, Gianfranco, Cattadori, Gaia, Scardovi, Angela B., Metra, Marco, Senni, Michele, Scrutinio, Domenico, Raimondo, Rosa, Emdin, Michele, Magrì, Damiano, Parati, Gianfranco, Re, Federica, Cicoira, Mariantonietta, Minà, Chiara, Limongelli, Giuseppe, Correale, Michele, Frigerio, Maria, Bussotti, Maurizio, Perna, Enrico, Battaia, Elisa, Guazzi, Marco, Badagliacca, Roberto, Di Lenarda, Andrea, Maggioni, Aldo, Passino, Claudio, Sciomer, Susanna, Pacileo, Giuseppe, Mapelli, Massimo, Vignati, Carlo, Lombardi, Carlo, Filardi, Pasquale Perrone, Agostoni, Piergiuseppe, Campodonico, J., Piepoli, M., Clemenza, F., Bonomi, A., Paolillo, S., Salvioni, E., Corra, U., Binno, S., Veglia, F., Lagioia, R., Sinagra, G., Cattadori, G., Scardovi, A. B., Metra, M., Senni, M., Scrutinio, D., Raimondo, R., Emdin, M., Magri, D., Parati, G., Re, F., Cicoira, M., Mina, C., Limongelli, G., Correale, M., Frigerio, M., Bussotti, M., Perna, E., Battaia, E., Guazzi, M., Badagliacca, R., Di Lenarda, A., Maggioni, A., Passino, C., Sciomer, S., Pacileo, G., Mapelli, M., Vignati, C., Lombardi, C., Filardi, P. P., Agostoni, P., Campodonico, J, Piepoli, M, Clemenza, F, Bonomi, A, Paolillo, S, Salvioni, E, Corrà, U, Binno, S, Veglia, F, Lagioia, R, Sinagra, G, Cattadori, G, Scardovi, A, Metra, M, Senni, M, Scrutinio, D, Raimondo, R, Emdin, M, Magrì, D, Parati, G, Re, F, Cicoira, M, Minà, C, Limongelli, G, Correale, M, Frigerio, M, Bussotti, M, Perna, E, Battaia, E, Guazzi, M, Badagliacca, R, Di Lenarda, A, Maggioni, A, Passino, C, Sciomer, S, Pacileo, G, Mapelli, M, Vignati, C, Lombardi, C, Filardi, P, and Agostoni, P

Subjects
Male, medicine.medical_specialty, Prognosi, medicine.medical_treatment, Cardiopulmonary exercise test, Prognosis, β-Blockers, Atrial fibrillation, Cardiology and Cardiovascular Medicine, Adrenergic beta-Antagonists, Dose dependence, heart failure, atrial fibrillation, prognosis, beta-blocker, cardiopulmonary exercise test, 030204 cardiovascular system & hematology, Follow-Up Studie, 03 medical and health sciences, 0302 clinical medicine, Retrospective Studie, Internal medicine, Atrial Fibrillation, medicine, Humans, In patient, 030212 general & internal medicine, Survival analysis, Aged, Retrospective Studies, Heart Failure, Entire population, Dose-Response Relationship, Drug, business.industry, Confounding, Adrenergic beta-Antagonist, Atrial fibrillation, Middle Aged, medicine.disease, Death, Treatment Outcome, Ventricular assist device, Heart failure, beta-blocker, Cardiology, β-Blockers, Female, business, Human, Follow-Up Studies
Abstract

The usefulness of β-blockers in heart failure (HF) patients with permanent atrial fibrillation (AF) has been questioned. Background: The usefulness of β-blockers in heart failure (HF) patients with permanent atrial fibrillation (AF) has been questioned. Methods and results: We analyzed data from HF patients (958 patients (801 males, 84%, age 67 ± 11 years)) with AF enrolled in the MECKI score database. We evaluated prognosis (composite of cardiovascular death, urgent heart transplant, or left ventricular assist device) of patients receiving β-blockers (n = 777, 81%) vs. those not treated with β-blockers (n = 181, 19%). We also analyzed the role β1-selectivity and the role of daily β-blocker dose. To account for different HF severity, Kaplan-Meier survival curves were normalized for relevant confounding factors and for treatment strategies. Dose was available in 629 patients. Median follow-up was 1312 (577–2304) days in the entire population, 1203 (614–2420) and 1325 (569–2300) days in patients not receiving and receiving β-blockers. 224 (23%, 54/1000 events/year), 163 (21%, 79/1000 events/year), and 61 (34%, 49/1000 events/year) events were recorded, respectively. At 10-year patients treated with β-blockers had a better outcome (HR 0.447, p < 0.01) with no effects as regards β1selective drugs (53%) vs. β1-β2 blockers (47%). Survival improved in parallel with β-blocker dose increase (HR 0.296, 0.496, 0.490 for the high, medium, and low dose vs. no β-blockers, p < 0.0001). Conclusion: HF patients with AF taking a β-blocker have a better outcome (with a survival improvement in parallel with daily dose but no differences as regards β1 selectivity) but this does not mean that β-blockers improve outcomes in these patients as we cannot control for all the potential confounders associated with β-blocker use.

Published
2018
Full Text
View/download PDF

4. Clinical Presentation and Outcome in a Contemporary Cohort of Patients With Acute Myocarditis

Author

Ammirati, Enrico, Cipriani, Manlio, Moro, Claudio, Raineri, Claudia, Pini, Daniela, Sormani, Paola, Mantovani, Riccardo, Varrenti, Marisa, Pedrotti, Patrizia, Conca, Cristina, Mafrici, Antonio, Grosu, Aurelia, Briguglia, Daniele, Guglielmetto, Silvia, Perego, Giovanni B, Colombo, Stefania, Caico, Salvatore I, Giannattasio, Cristina, Maestroni, Alberto, Carubelli, Valentina, Metra, Marco, Lombardi, Carlo, Campodonico, Jeness, Agostoni, Piergiuseppe, Peretto, Giovanni, Scelsi, Laura, Turco, Annalisa, Di Tano, Giuseppe, Campana, Carlo, Belloni, Armando, Morandi, Fabrizio, Mortara, Andrea, Cirò, Antonio, Senni, Michele, Gavazzi, Antonello, Frigerio, Maria, Oliva, Fabrizio, Camici, Paolo G, Ammirati, Enrico, Cipriani, Manlio, Moro, Claudio, Raineri, Claudia, Pini, Daniela, Sormani, Paola, Mantovani, Riccardo, Varrenti, Marisa, Pedrotti, Patrizia, Conca, Cristina, Mafrici, Antonio, Grosu, Aurelia, Briguglia, Daniele, Guglielmetto, Silvia, Perego, Giovanni B, Colombo, Stefania, Caico, Salvatore I, Giannattasio, Cristina, Maestroni, Alberto, Carubelli, Valentina, Metra, Marco, Lombardi, Carlo, Campodonico, Jene, Agostoni, Piergiuseppe, Peretto, Giovanni, Scelsi, Laura, Turco, Annalisa, Di Tano, Giuseppe, Campana, Carlo, Belloni, Armando, Morandi, Fabrizio, Mortara, Andrea, Cirò, Antonio, Senni, Michele, Gavazzi, Antonello, Frigerio, Maria, Oliva, Fabrizio, and Camici, Paolo G

Subjects
myocarditi, treatment outcome, magnetic resonance imaging, biopsy, heart transplantation
Abstract

There is controversy about the outcome of patients with acute myocarditis (AM), and data are lacking on how patients admitted with suspected AM are managed. We report characteristics, in-hospital management, and long-term outcome of patients with AM based on a retrospective multicenter registry from 19 Italian hospitals.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results